404
+1-313-307-4176
Chronic Idiopathic Constipation (CIC) Drugs Market Report
Chronic Idiopathic Constipation (CIC) Drugs Market Trends, Dynamics & Market Insights: 2022-2028
Chronic Idiopathic Constipation (CIC) Drugs Market, By Product Type (Lubiprostone, Linaclotide, Others), End-User (Hospitals & Clinics, Ambulatory Surgical Centres, Long Term Care Centres, Others), and Region - COVID-19 Impact Analysis and Forecast to 2026.
This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Chronic Idiopathic Constipation (CIC) Drugs market. The historic years considered for the study are 2016-2019, the base year is 2020, and the forecast period is 2021-2026.
The Chronic Idiopathic Constipation (CIC) Drugs market is projected to grow from USD 4.38 billion in 2021 to USD 6.93 billion by 2028 at a CAGR of around 6.72% during the forecast period of 2022-2028.
Constipation is defined as a health condition with decreased stool frequency or issues in passant stool. Reduced or tough stool passage is during hard lumpy stools, straining, incomplete bowel actions, incomplete evacuation, and the necessity for manual elimination of stool. Chronic idiopathic constipation (CIC) is defined as a persistent or extreme continuation of the above-mentioned signs and symptoms.
The growth of the chronic idiopathic constipation (CIC) drugs market is primarily driven by increasing incidences of chronic constipation health disorder. Expanding geriatric populace across geographies coupled with rising spending on healthcare is expected to propel the market growth at a significant rate during the review period. Additionally, a growing emphasis on research and development activities for novel drug development is likely to create lucrative opportunities for the market players during the review period.
The outbreak of the COVID-19 virus has affected the growth of the healthcare industry significantly. Stringent lockdown measures and restricted movement of people affected the product supply for a short period and thus, affected the market growth.
Key players operating in the Chronic Idiopathic Constipation (CIC) Drugs market are-
By end-user, the chronic idiopathic constipation (CIC) drugs market has been bifurcated into hospitals & clinics, ambulatory surgical centers, long-term care centers, and others. Under these, the hospitals & clinics segment accounted for the largest market share in 2021 and is projected to register significant growth during the review period.
By region, the market in North America accounted for the largest market share in 2021 and is projected to grow at a significant CAGR during the assessment period. The regional growth is primarily attributed to the high prevalence of chronic constipation particularly among the geriatric populace coupled with the presence of key market players such as Actavis Generics (US) and Pfizer Inc. (US). The market growth in the Asia-Pacific region is expected to be driven by rising awareness among consumers regarding CIC drugs coupled with the rising geriatric population in developing countries, particularly China and India.
This report offers high-quality insights and is the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact book, press release, journals, investor presentation, white papers, patents, and articles have been leveraged to gather the data. We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both the qualitative and quantitative insights.
This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:
Here is the list of the group of customers that the Chronic idiopathic constipation (CIC) Drugs Market hopes to have the greatest opportunity to convert-
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
The chronic idiopathic constipation drugs market is expected to witness an impressive growth of 6.72% CAGR during 2022-2028.
Actavis Generics (US), The Chugai Pharmaceutical Co., Ltd (Japan), Ferring International Center, S.A. (Switzerland), Synergy Pharmaceuticals (US), Pfizer Inc. (US), GlaxoSmithKline plc (UK), F. Hoffmann-La Roche AG (Switzerland), Sanofi S.A. (France), Bayer AG (Germany), Salix Pharma-ceuticals, Inc. (US), Sucampo Pharmaceuticals, Inc. (US), Ironwood Pharmaceuticals, Inc (US) and Progenics Pharmaceuticals, Inc. (US) are among the key players in the market.
The chronic idiopathic constipation drugs market size is expected to reach USD 6.93 billion in 2028.
The hospitals & clinics segment is expected to register significant growth in the market in the coming years.
North America accounted for the largest share in the market in 2021.
Chronic idiopathic constipation (CIC) Drugs distributors, Chronic idiopathic constipation (CIC) Drugs suppliers, Chronic Idiopathic Constipation (CIC) Drugs manufacturers, Logistics organizations, Government bodies are the target audience in the market.
WE ACCEPT
